Showing results (351-360 of 413) with videos related to
Sort By:
Pageof 42
Clinical Chemistry|December 23, 2006
Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancerThomas Steuber, Andrew J Vickers, Angel M Serio, et al.Endocrinology|October 1, 1993
Natriuretic hormone receptors and actions on bone endothelial cellsM L De Feo, F Franceschelli, U Frediani, et al.Journal of Endocrinological Investigation|September 3, 2010
Evaluation of the anterior pituitary function in the acute phase after spontaneous subarachnoid hemorrhageG Parenti, P C Cecchi, B Ragghianti, et al.Molecular Human Reproduction|January 11, 2005
Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferensR Mancina, S Filippi, M Marini, et al.Journal of Endocrinological Investigation|October 7, 2011
A simple ultrasound score for the identification of candidates to fine needle aspiration of thyroid nodulesL Petrone, E Mannucci, M L De Feo, et al.British Journal of Cancer|September 14, 2006
Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cellsI Cellai, S Benvenuti, P Luciani, et al.The Journal of Biological Chemistry|January 14, 2001
Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytesA Bonacchi, P Romagnani, R G Romanelli, et al.Medical and Pediatric Oncology|July 24, 2001
Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotideC Orlando, C C Raggi, L Bagnoni, et al.Journal of Endocrinological Investigation|November 13, 2007
Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cellsS Benvenuti, I Cellai, P Luciani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened populationDavid Ulmert, Angel M Serio, Matthew F O'Brien, et al.Pageof 42